Hepion Pharmaceuticals Company Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States.
It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1.
The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Kaouthar Lbiati |
Contact Details
Address: 55 Madison Avenue Morristown, Delaware 07960 United States | |
| Phone | (732) 902-4000 |
| Website | hepionpharma.com |
Stock Details
| Ticker Symbol | HEPA |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US4268971045 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kaouthar Lbiati M.D. | Interim Chief Executive Officer and Director |
| Sharen Pyatetskaya | Director of Investor Relations |